{"id":55866,"date":"2025-12-21T11:19:41","date_gmt":"2025-12-21T02:19:41","guid":{"rendered":"https:\/\/www.marketresearch.jp\/reports\/?p=55866"},"modified":"2026-09-25T23:37:12","modified_gmt":"2026-09-25T14:37:12","slug":"glucagon-like-peptide-1-agonists-market","status":"publish","type":"post","link":"https:\/\/www.marketresearch.jp\/reports\/glucagon-like-peptide-1-agonists-market\/","title":{"rendered":"\u4e16\u754c\u306eGLP-1\u30a2\u30b4\u30cb\u30b9\u30c8\u5e02\u5834\uff1a\u88fd\u54c1\u5225\uff08\u30c7\u30e5\u30e9\u30b0\u30eb\u30c1\u30c9\u3001\u30a8\u30ad\u30bb\u30ca\u30c1\u30c9\u3001\u30ea\u30e9\u30b0\u30eb\u30c1\u30c9\u306a\u3069\uff09\u3001\u9069\u5fdc\u75c7\u5225\uff08\u80a5\u6e80\u30012\u578b\u7cd6\u5c3f\u75c5\u306a\u3069\uff09\u3001\u6295\u4e0e\u7d4c\u8def\u5225\u3001\u6d41\u901a\u30c1\u30e3\u30cd\u30eb\u5225\u3001\u30a8\u30f3\u30c9\u30e6\u30fc\u30b6\u30fc\u5225\u5206\u6790 &#8211; \u4e16\u754c\u5e02\u5834\u4e88\u6e2c 2025\u5e74\uff5e2032\u5e74"},"content":{"rendered":"<p><img decoding=\"async\" src=\"https:\/\/www.marketresearch.jp\/reports\/wp-content\/uploads\/2025\/12\/glucagon-like-peptide-1-agonists-statistics.png\" alt=\"Market Statistics\" style=\"max-width:100%;\"><\/p>\n<p>\u4ee5\u4e0b\u306bTOC\u306e\u65e5\u672c\u8a9e\u8a33\u3068\u8a73\u7d30\u306a\u968e\u5c64\u69cb\u9020\u3092\u793a\u3057\u307e\u3059\u3002<\/p>\n<p>&#8212;<\/p>\n<p>## \u76ee\u6b21<\/p>\n<p>1.  **\u5e8f\u6587**<br \/>\n    *   \u5e02\u5834\u30bb\u30b0\u30e1\u30f3\u30c6\u30fc\u30b7\u30e7\u30f3\u3068\u30ab\u30d0\u30ec\u30c3\u30b8<br \/>\n    *   \u8abf\u67fb\u5bfe\u8c61\u5e74<br \/>\n    *   \u901a\u8ca8<br \/>\n    *   \u8a00\u8a9e<br \/>\n    *   \u30b9\u30c6\u30fc\u30af\u30db\u30eb\u30c0\u30fc<br \/>\n2.  **\u8abf\u67fb\u65b9\u6cd5**<br \/>\n3.  **\u30a8\u30b0\u30bc\u30af\u30c6\u30a3\u30d6\u30b5\u30de\u30ea\u30fc**<br \/>\n4.  **\u5e02\u5834\u6982\u8981**<br \/>\n5.  **\u5e02\u5834\u30a4\u30f3\u30b5\u30a4\u30c8**<br \/>\n    *   \u7d4c\u53e3GLP-1\u30a2\u30b4\u30cb\u30b9\u30c8\u88fd\u5264\u306e\u767b\u5834\u304c\u60a3\u8005\u306e\u670d\u85ac\u9075\u5b88\u3068\u5229\u4fbf\u6027\u3092\u5411\u4e0a<br \/>\n    *   \u80a5\u6e80\u7ba1\u7406\u3078\u306eGLP-1\u30a2\u30b4\u30cb\u30b9\u30c8\u306e\u62e1\u5927\u304c\u4fa1\u683c\u7af6\u4e89\u3068\u30a2\u30af\u30bb\u30b9\u306b\u95a2\u3059\u308b\u8b70\u8ad6\u3092\u63d0\u8d77<br \/>\n    *   \u88fd\u85ac\u4f01\u696d\u3068\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u4f01\u696d\u9593\u306e\u6226\u7565\u7684\u30d1\u30fc\u30c8\u30ca\u30fc\u30b7\u30c3\u30d7\u306b\u3088\u308bGLP-1\u6cbb\u7642\u5411\u3051\u30c7\u30b8\u30bf\u30eb\u30b5\u30dd\u30fc\u30c8\u30c4\u30fc\u30eb\u306e\u958b\u767a<br \/>\n    *   \u4f53\u91cd\u7ba1\u7406\u76ee\u7684\u3067\u306eGLP-1\u30a2\u30b4\u30cb\u30b9\u30c8\u306e\u9069\u5fdc\u5916\u4f7f\u7528\u306e\u5897\u52a0\u304c\u898f\u5236\u5f53\u5c40\u306e\u76e3\u8996\u3068\u5b89\u5168\u6027\u30e2\u30cb\u30bf\u30ea\u30f3\u30b0\u3092\u4fc3\u3059<br \/>\n    *   GLP-1\u3068GIP\u53d7\u5bb9\u4f53\u3092\u7d44\u307f\u5408\u308f\u305b\u305f\u6b21\u4e16\u4ee3\u30c7\u30e5\u30a2\u30eb\u30a2\u30b4\u30cb\u30b9\u30c8\u306e\u5c0e\u5165\u306b\u3088\u308b\u4ee3\u8b1d\u6539\u5584\u52b9\u679c\u306e\u5411\u4e0a<br \/>\n    *   \u30d0\u30a4\u30aa\u30b7\u30df\u30e9\u30fcGLP-1\u30a2\u30b4\u30cb\u30b9\u30c8\u627f\u8a8d\u3078\u306e\u6ce8\u76ee\u306e\u9ad8\u307e\u308a\u304c\u65e2\u5b58\u5e02\u5834\u3067\u306e\u30b3\u30b9\u30c8\u7af6\u4e89\u3092\u6fc0\u5316<br \/>\n6.  **2025\u5e74\u7c73\u56fd\u95a2\u7a0e\u306e\u7d2f\u7a4d\u7684\u5f71\u97ff**<br \/>\n7.  **2025\u5e74\u4eba\u5de5\u77e5\u80fd\u306e\u7d2f\u7a4d\u7684\u5f71\u97ff**<br \/>\n8.  **GLP-1\u30a2\u30b4\u30cb\u30b9\u30c8\u5e02\u5834\uff1a\u88fd\u54c1\u5225**<br \/>\n    *   \u30c7\u30e5\u30e9\u30b0\u30eb\u30c1\u30c9 (Dulaglutide)<br \/>\n    *   \u30a8\u30ad\u30bb\u30ca\u30c1\u30c9 (Exenatide)<br \/>\n    *   \u30ea\u30e9\u30b0\u30eb\u30c1\u30c9 (Liraglutide)<br \/>\n    *   \u30bb\u30de\u30b0\u30eb\u30c1\u30c9 (Semaglutide)<br \/>\n9.  **GLP-1\u30a2\u30b4\u30cb\u30b9\u30c8\u5e02\u5834\uff1a\u9069\u5fdc\u75c7\u5225**<br \/>\n    *   \u80a5\u6e80 (Obesity)<br \/>\n    *   2\u578b\u7cd6\u5c3f\u75c5 (Type 2 Diabetes)<br \/>\n10. **GLP-1\u30a2\u30b4\u30cb\u30b9\u30c8\u5e02\u5834\uff1a\u6295\u4e0e\u7d4c\u8def\u5225**<br \/>\n    *   \u7d4c\u53e3 (Oral)<br \/>\n    *   \u76ae\u4e0b (Subcutaneous)<br \/>\n11. **GLP-1\u30a2\u30b4\u30cb\u30b9\u30c8\u5e02\u5834\uff1a\u6d41\u901a\u30c1\u30e3\u30cd\u30eb\u5225**<br \/>\n    *   \u75c5\u9662\u85ac\u5c40 (Hospital Pharmacy)<br \/>\n    *   \u30aa\u30f3\u30e9\u30a4\u30f3\u85ac\u5c40 (Online Pharmacy)<br \/>\n    *   \u5c0f\u58f2\u85ac\u5c40 (Retail Pharmacy)<br \/>\n12. **GLP-1\u30a2\u30b4\u30cb\u30b9\u30c8\u5e02\u5834\uff1a\u30a8\u30f3\u30c9\u30e6\u30fc\u30b6\u30fc\u5225**<br \/>\n    *   \u8a3a\u7642\u6240 (Clinic)<br \/>\n    *   \u5728\u5b85\u533b\u7642 (Homecare)<br \/>\n    *   \u75c5\u9662 (Hospital)<br \/>\n13. **GLP-1\u30a2\u30b4\u30cb\u30b9\u30c8\u5e02\u5834\uff1a\u5730\u57df\u5225**<br \/>\n    *   \u7c73\u5dde (Americas)<br \/>\n        *   \u5317\u7c73 (North America)<br \/>\n        *   \u4e2d\u5357\u7c73 (Latin America)<br \/>\n    *   \u6b27\u5dde\u3001\u4e2d\u6771\u3001\u30a2\u30d5\u30ea\u30ab (Europe, Middle East &#038; Africa)<br \/>\n        *   \u6b27\u5dde (Europe)<br \/>\n        *   \u4e2d\u6771 (Middle East)<br \/>\n        *   \u30a2\u30d5\u30ea\u30ab (Africa)<br \/>\n    *   \u30a2\u30b8\u30a2\u592a\u5e73\u6d0b (Asia-Pacific)<br \/>\n14. **GLP-1\u30a2\u30b4\u30cb\u30b9\u30c8\u5e02\u5834\uff1a\u30b0\u30eb\u30fc\u30d7\u5225**<br \/>\n    *   ASEAN (ASEAN)<br \/>\n    *   GCC (GCC)<br \/>\n    *   \u6b27\u5dde\u9023\u5408 (European Union)<br \/>\n    *   BRICS (BRICS)<br \/>\n    *   G7 (G7)<br \/>\n    *   NATO (NATO)<br \/>\n15. **GLP-1\u30a2\u30b4\u30cb\u30b9\u30c8\u5e02\u5834\uff1a\u56fd\u5225**<br \/>\n    *   \u7c73\u56fd (United States)<br \/>\n    *   \u30ab\u30ca\u30c0 (Canada)<br \/>\n    *   \u30e1\u30ad\u30b7\u30b3 (Mexico)<br \/>\n    *   \u30d6\u30e9\u30b8\u30eb (Brazil)<br \/>\n    *   \u82f1\u56fd (United Kingdom)<br \/>\n    *   \u30c9\u30a4\u30c4 (Germany)<br \/>\n    *   \u30d5\u30e9\u30f3\u30b9 (France)<br \/>\n    *   \u30ed\u30b7\u30a2 (Russia)<br \/>\n    *   \u30a4\u30bf\u30ea\u30a2 (Italy)<br \/>\n    *   \u30b9\u30da\u30a4\u30f3 (Spain)<br \/>\n    *   \u4e2d\u56fd (China)<br \/>\n    *   \u30a4\u30f3\u30c9 (India)<br \/>\n    *   \u65e5\u672c (Japan)<br \/>\n    *   \u30aa\u30fc\u30b9\u30c8\u30e9\u30ea\u30a2 (Australia)<br \/>\n    *   \u97d3\u56fd (South Korea)<br \/>\n16. **\u7af6\u4e89\u74b0\u5883**<br \/>\n    *   \u5e02\u5834\u30b7\u30a7\u30a2\u5206\u6790\u30012024\u5e74<br \/>\n    *   FPNV\u30dd\u30b8\u30b7\u30e7\u30cb\u30f3\u30b0\u30de\u30c8\u30ea\u30c3\u30af\u30b9\u30012024\u5e74<br \/>\n    *   \u7af6\u5408\u5206\u6790<br \/>\n        *   \u30ce\u30dc \u30ce\u30eb\u30c7\u30a3\u30b9\u30af A\/S (Novo Nordisk A\/S)<br \/>\n        *   \u30a4\u30fc\u30e9\u30a4\u30ea\u30ea\u30fc\u30fb\u30a2\u30f3\u30c9\u30fb\u30ab\u30f3\u30d1\u30cb\u30fc (Eli Lilly and Company)<br \/>\n        *   \u30a2\u30b9\u30c8\u30e9\u30bc\u30cd\u30ab plc (AstraZeneca plc)<br \/>\n17. **\u56f3\u8868\u30ea\u30b9\u30c8 [\u5408\u8a08: 30]**<br \/>\n    *   \u4e16\u754c\u306eGLP-1\u30a2\u30b4\u30cb\u30b9\u30c8\u5e02\u5834\u898f\u6a21\u30012018-2032\u5e74 (\u767e\u4e07\u7c73\u30c9\u30eb)<br \/>\n    *   \u4e16\u754c\u306eGLP-1\u30a2\u30b4\u30cb\u30b9\u30c8\u5e02\u5834\u898f\u6a21\uff1a\u88fd\u54c1\u5225\u30012024\u5e74\u5bfe2032\u5e74 (%)<br \/>\n    *   \u4e16\u754c\u306eGLP-1\u30a2\u30b4\u30cb\u30b9\u30c8\u5e02\u5834\u898f\u6a21\uff1a\u88fd\u54c1\u5225\u30012024\u5e74\u5bfe2025\u5e74\u5bfe2032\u5e74 (\u767e\u4e07\u7c73\u30c9\u30eb)<br \/>\n    *   \u4e16\u754c\u306eGLP-1\u30a2\u30b4\u30cb\u30b9\u30c8\u5e02\u5834\u898f\u6a21\uff1a\u9069\u5fdc\u75c7\u5225\u30012024\u5e74\u5bfe2032\u5e74 (%)<br \/>\n    *   \u4e16\u754c\u306eGLP-1\u30a2\u30b4\u30cb\u30b9\u30c8\u5e02\u5834\u898f\u6a21\uff1a\u9069\u5fdc\u75c7\u5225\u30012024\u5e74\u5bfe2025\u5e74\u5bfe2032\u5e74 (\u767e\u4e07\u7c73\u30c9\u30eb)<br \/>\n    *   \u4e16\u754c\u306eGLP-1\u30a2\u30b4\u30cb\u30b9\u30c8\u5e02\u5834\u898f\u6a21\uff1a\u6295\u4e0e\u7d4c\u8def\u5225\u30012024\u5e74\u5bfe2032\u5e74 (%)<br \/>\n    *   \u4e16\u754c\u306eGLP-1\u30a2\u30b4\u30cb\u30b9\u30c8\u5e02\u5834\u898f\u6a21\uff1a\u6295\u4e0e\u7d4c\u8def\u5225\u30012024\u5e74\u5bfe2025\u5e74\u5bfe2032\u5e74 (\u767e\u4e07\u7c73\u30c9\u30eb)<br \/>\n    *   \u4e16\u754c\u306eGLP-1\u30a2\u30b4\u30cb\u30b9\u30c8\u5e02\u5834\u898f\u6a21\uff1a\u6d41\u901a\u30c1\u30e3\u30cd\u30eb\u5225\u30012024\u5e74\u5bfe2032\u5e74 (%)<br \/>\n    *   \u4e16\u754c\u306eGLP-1\u30a2\u30b4\u30cb\u30b9\u30c8\u5e02\u5834\u898f\u6a21\uff1a\u6d41\u901a\u30c1\u30e3\u30cd\u30eb\u5225\u30012024\u5e74\u5bfe2025\u5e74\u5bfe2032\u5e74 (\u767e\u4e07\u7c73\u30c9\u30eb)<br \/>\n    *   \u4e16\u754c\u306eGLP-1\u30a2\u30b4\u30cb\u30b9\u30c8\u5e02\u5834\u898f\u6a21\uff1a\u30a8\u30f3\u30c9\u30e6\u30fc\u30b6\u30fc\u5225\u30012024\u5e74\u5bfe2032\u5e74 (%)<br \/>\n    *   \u4e16\u754c\u306eGLP-1\u30a2\u30b4\u30cb\u30b9\u30c8\u5e02\u5834\u898f\u6a21\uff1a\u30a8\u30f3\u30c9\u30e6\u30fc\u30b6\u30fc\u5225\u30012024\u5e74\u5bfe2025\u5e74\u5bfe2032\u5e74 (\u767e\u4e07\u7c73\u30c9\u30eb)<br \/>\n    *   \u4e16\u754c\u306eGLP-1\u30a2\u30b4\u30cb\u30b9\u30c8\u5e02\u5834\u898f\u6a21\uff1a\u5730\u57df\u5225\u30012024\u5e74\u5bfe2025\u5e74\u5bfe2032\u5e74 (\u767e\u4e07\u7c73\u30c9\u30eb)<br \/>\n    *   \u7c73\u5dde\u306eGLP-1\u30a2\u30b4\u30cb\u30b9\u30c8\u5e02\u5834\u898f\u6a21\uff1a\u30b5\u30d6\u5730\u57df\u5225\u30012024\u5e74\u5bfe2025\u5e74\u5bfe2032\u5e74 (\u767e\u4e07\u7c73\u30c9\u30eb)<br \/>\n    *   \u5317\u7c73\u306eGLP-1\u30a2\u30b4\u30cb\u30b9\u30c8\u5e02\u5834\u898f\u6a21\uff1a\u56fd\u5225\u30012024\u5e74\u5bfe2025\u5e74\u5bfe2032\u5e74 (\u767e\u4e07\u7c73\u30c9\u30eb)<br \/>\n    *   \u4e2d\u5357\u7c73\u306eGLP-1\u30a2\u30b4\u30cb\u30b9\u30c8\u5e02\u5834\u898f\u6a21\uff1a\u56fd\u5225\u30012024\u5e74\u5bfe2025\u5e74\u5bfe2032\u5e74 (\u767e\u4e07\u7c73\u30c9\u30eb)<br \/>\n    *   \u6b27\u5dde\u3001\u4e2d\u6771\u3001\u30a2\u30d5\u30ea\u30ab\u306eGLP-1\u30a2\u30b4\u30cb\u30b9\u30c8\u5e02\u5834\u898f\u6a21\uff1a\u30b5\u30d6\u5730\u57df\u5225\u30012024\u5e74\u5bfe2025\u5e74\u5bfe2032\u5e74 (\u767e\u4e07\u7c73\u30c9\u30eb)<br \/>\n    *   \u6b27\u5dde\u306eGLP-1\u30a2\u30b4\u30cb\u30b9\u30c8\u5e02\u5834\u898f\u6a21\uff1a\u56fd\u5225\u30012024\u5e74\u5bfe2025\u5e74\u5bfe2032\u5e74 (\u767e\u4e07\u7c73\u30c9\u30eb)<br \/>\n    *   \u4e2d\u6771\u306eGLP-1\u30a2\u30b4\u30cb\u30b9\u30c8\u5e02\u5834\u898f\u6a21\uff1a\u56fd\u5225\u30012024\u5e74\u5bfe2025\u5e74\u5bfe2032\u5e74 (\u767e\u4e07\u7c73\u30c9\u30eb)<br \/>\n    *   \u30a2\u30d5\u30ea\u30ab\u306eGLP-1\u30a2\u30b4\u30cb\u30b9\u30c8\u5e02\u5834\u898f\u6a21\uff1a\u56fd\u5225\u30012024\u5e74\u5bfe2025\u5e74\u5bfe2032\u5e74 (\u767e\u4e07\u7c73\u30c9\u30eb)<br \/>\n    *   \u30a2\u30b8\u30a2\u592a\u5e73\u6d0b\u306eGLP-1\u30a2\u30b4\u30cb\u30b9\u30c8\u5e02\u5834\u898f\u6a21\uff1a\u56fd\u5225\u30012024\u5e74\u5bfe2025\u5e74\u5bfe2032\u5e74 (\u767e\u4e07\u7c73\u30c9\u30eb)<br \/>\n    *   \u4e16\u754c\u306eGLP-1\u30a2\u30b4\u30cb\u30b9\u30c8\u5e02\u5834\u898f\u6a21\uff1a\u30b0\u30eb\u30fc\u30d7\u5225\u30012024\u5e74\u5bfe2025\u5e74\u5bfe2032\u5e74 (\u767e\u4e07\u7c73\u30c9\u30eb)<br \/>\n    *   ASEAN\u306eGLP-1\u30a2\u30b4\u30cb\u30b9\u30c8\u5e02\u5834\u898f\u6a21\uff1a\u56fd\u5225\u30012024\u5e74\u5bfe2025\u5e74\u5bfe2032\u5e74 (\u767e\u4e07\u7c73\u30c9\u30eb)<br \/>\n    *   GCC\u306eGLP-1\u30a2\u30b4\u30cb\u30b9\u30c8\u5e02\u5834\u898f\u6a21\uff1a\u56fd\u5225\u30012024\u5e74\u5bfe2025\u5e74\u5bfe2032\u5e74 (\u767e\u4e07\u7c73\u30c9\u30eb)<br \/>\n    *   \u6b27\u5dde\u9023\u5408\u306eGLP-1\u30a2\u30b4\u30cb\u30b9\u30c8\u5e02\u5834\u898f\u6a21\uff1a\u56fd\u5225\u30012024\u5e74\u5bfe2025\u5e74\u5bfe2032\u5e74 (\u767e\u4e07\u7c73\u30c9\u30eb)<br \/>\n    *   BRICS\u306eGLP-1\u30a2\u30b4\u30cb\u30b9\u30c8\u5e02\u5834\u898f\u6a21\uff1a\u56fd\u5225\u30012024\u5e74\u5bfe2025\u5e74\u5bfe2032\u5e74 (\u767e\u4e07\u7c73\u30c9\u30eb)<br \/>\n    *   G7\u306eGLP-1\u30a2\u30b4\u30cb\u30b9\u30c8\u5e02\u5834\u898f\u6a21\uff1a\u56fd\u5225\u30012024\u5e74\u5bfe2025\u5e74\u5bfe2032\u5e74 (\u767e\u4e07\u7c73\u30c9\u30eb)<br \/>\n    *   NATO\u306eGLP-1\u30a2\u30b4\u30cb\u30b9\u30c8\u5e02\u5834\u898f\u6a21\uff1a\u56fd\u5225\u30012024\u5e74\u5bfe2025\u5e74\u5bfe2032\u5e74 (\u767e\u4e07\u7c73\u30c9\u30eb)<br \/>\n    *   \u4e16\u754c\u306eGLP-1\u30a2\u30b4\u30cb\u30b9\u30c8\u5e02\u5834\u898f\u6a21\uff1a\u56fd\u5225\u30012024\u5e74\u5bfe2025\u5e74\u5bfe2032\u5e74 (\u767e\u4e07\u7c73\u30c9\u30eb)<br \/>\n    *   GLP-1\u30a2\u30b4\u30cb\u30b9\u30c8\u5e02\u5834\u30b7\u30a7\u30a2\uff1a\u4e3b\u8981\u4f01\u696d\u5225\u30012024\u5e74<br \/>\n    *   GLP-1\u30a2\u30b4\u30cb\u30b9\u30c8\u5e02\u5834\u3001FPNV\u30dd\u30b8\u30b7\u30e7\u30cb\u30f3\u30b0\u30de\u30c8\u30ea\u30c3\u30af\u30b9\u30012024\u5e74<br \/>\n18. **\u8868\u30ea\u30b9\u30c8 [\u5408\u8a08: 423]**<br \/>\n    *   GLP-1\u30a2\u30b4\u30cb\u30b9\u30c8\u5e02\u5834\u306e\u30bb\u30b0\u30e1\u30f3\u30c6\u30fc\u30b7\u30e7\u30f3\u3068\u30ab\u30d0\u30ec\u30c3\u30b8<br \/>\n    *   \u4e16\u754c\u306eGLP-1\u30a2\u30b4\u30cb\u30b9\u30c8\u5e02\u5834\u898f\u6a21\u30012018-2024\u5e74 (\u767e\u4e07\u7c73\u30c9\u30eb)<br \/>\n    *   \u4e16\u754c\u306eGLP-1\u30a2\u30b4\u30cb\u30b9\u30c8\u5e02\u5834\u898f\u6a21\u30012025-2032\u5e74 (\u767e\u4e07\u7c73\u30c9\u30eb)<br \/>\n    *   \u4e16\u754c\u306eGLP-1\u30a2\u30b4\u30cb\u30b9\u30c8\u5e02\u5834\u898f\u6a21\uff1a\u88fd\u54c1\u5225\u30012018-2024\u5e74 (\u767e\u4e07\u7c73\u30c9\u30eb)<br \/>\n    *   \u4e16\u754c\u306eGLP-1\u30a2\u30b4\u30cb\u30b9\u30c8\u5e02\u5834 (\u203b\u5165\u529b\u304c\u9014\u4e2d\u3067\u9014\u5207\u308c\u3066\u3044\u307e\u3059)<\/p>\n<p>&#8230;&#8230;&#8230;&#8230; (\u4ee5\u4e0b\u7701\u7565)<\/p>\n","protected":false},"excerpt":{"rendered":"<p>GLP-1\u30a2\u30b4\u30cb\u30b9\u30c8\u5e02\u5834\u306f\u30012025\u5e74\u304b\u30892032\u5e74\u306b\u304b\u3051\u3066\u30012\u578b\u7cd6\u5c3f\u75c5\u304a\u3088\u3073\u80a5\u6e80\u6cbb\u7642\u306b\u304a\u3051\u308b\u9769\u65b0\u7684\u306a\u30a4\u30f3\u30af\u30ec\u30c1\u30f3\u6a21\u5023\u7642\u6cd5\u3068\u3057\u3066\u3001\u305d\u306e\u91cd\u8981\u6027\u3092\u5897\u3057\u3066\u3044\u307e\u3059\u3002\u3053\u308c\u3089\u306e\u85ac\u5264\u306f\u3001\u5185\u56e0\u6027\u30db\u30eb\u30e2\u30f3\u3067\u3042\u308b\u30b0\u30eb\u30ab\u30b4\u30f3\u69d8\u30da\u30d7\u30c1\u30c9-1\uff08GLP-1\uff09\u306e\u53d7\u5bb9\u4f53\u3092\u6d3b\u6027\u5316\u3059\u308b\u3053\u3068\u3067\u3001\u30a4\u30f3\u30b9\u30ea\u30f3\u5206\u6ccc\u306e\u8abf\u7bc0\u3001\u30b0\u30eb\u30ab\u30b4\u30f3\u7523\u751f\u306e\u6291\u5236\u3001\u80c3\u5185\u5bb9\u6392\u51fa\u306e\u9045\u5ef6\u3068\u3044\u3063\u305f\u591a\u9762\u7684\u306a\u4f5c\u7528\u3092\u767a\u63ee\u3057\u3001\u8840\u7cd6\u30b3\u30f3\u30c8\u30ed\u30fc\u30eb\u3068\u4f53\u91cd\u7ba1\u7406\u306b\u9855\u8457\u306a\u6539\u5584\u3092\u3082\u305f\u3089\u3057\u307e\u3059\u3002\u30c7\u30e5\u30e9\u30b0\u30eb\u30c1\u30c9\u3001\u30a8\u30ad\u30bb\u30ca\u30c1\u30c9\u3001\u30ea\u30e9\u30b0\u30eb\u30c1\u30c9\u3001\u30bb\u30de\u30b0\u30eb\u30c1\u30c9\u3068\u3044\u3063\u305f\u4e3b\u8981\u306aGLP-1\u30a2\u30b4\u30cb\u30b9\u30c8\u306f\u3001\u4ee3\u8b1d\u6027\u75be\u60a3\u6cbb\u7642\u306e\u790e\u77f3\u3068\u3057\u3066\u78ba\u7acb\u3055\u308c\u3001\u60a3\u8005\u306e\u8ee2\u5e30\u3092\u5287\u7684\u306b\u5909\u9769\u3057\u3066\u3044\u307e\u3059\u3002<\/p>\n<p>**\u5e02\u5834\u6982\u8981**<br \/>\n\u5e02\u5834\u306e\u9032\u5316\u306f\u3001\u9577\u671f\u4f5c\u7528\u578b\u88fd\u5264\u306e\u512a\u4f4d\u6027\u3092\u793a\u3059\u4e00\u9023\u306e\u753b\u671f\u7684\u306a\u81e8\u5e8a\u8a66\u9a13\u306b\u3088\u3063\u3066\u727d\u5f15\u3055\u308c\u3066\u304d\u307e\u3057\u305f\u3002\u90311\u56de\u6295\u4e0e\u306e\u30a8\u30ad\u30bb\u30ca\u30c1\u30c9\u3084\u30bb\u30de\u30b0\u30eb\u30c1\u30c9\u306f\u3001\u77ed\u6642\u9593\u4f5c\u7528\u578b\u3068\u6bd4\u8f03\u3057\u3066HbA1c\u306e\u3088\u308a\u5927\u304d\u306a\u4f4e\u4e0b\u3092\u793a\u3057\u3001\u30ea\u30e9\u30b0\u30eb\u30c1\u30c9\u3084\u30c7\u30e5\u30e9\u30b0\u30eb\u30c1\u30c9\u306f\u826f\u597d\u306a\u5fcd\u5bb9\u6027\u30d7\u30ed\u30d5\u30a1\u30a4\u30eb\u3067\u6301\u7d9a\u7684\u306a\u8840\u7cd6\u30b3\u30f3\u30c8\u30ed\u30fc\u30eb\u3092\u5b9f\u73fe\u3057\u3066\u3044\u307e\u3059\u3002\u3053\u308c\u3089\u306e\u85ac\u5264\u306f\u8840\u7cd6\u964d\u4e0b\u4f5c\u7528\u306b\u52a0\u3048\u3066\u3001\u5fc3\u8840\u7ba1\u304a\u3088\u3073\u814e\u81d3\u306e\u8ee2\u5e30\u306b\u3082\u8ffd\u52a0\u7684\u306a\u5229\u76ca\u3092\u3082\u305f\u3089\u3057\u3001\u78ba\u7acb\u3055\u308c\u305f\u5fc3\u8840\u7ba1\u75be\u60a3\u3084\u9ad8\u3044\u814e\u81d3\u30ea\u30b9\u30af\u30d7\u30ed\u30d5\u30a1\u30a4\u30eb\u3092\u6301\u3064\u60a3\u8005\u3078\u306e\u4f7f\u7528\u3092\u652f\u6301\u3057\u3066\u3044\u307e\u3059\u3002<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.marketresearch.jp\/reports\/wp-json\/wp\/v2\/posts\/55866"}],"collection":[{"href":"https:\/\/www.marketresearch.jp\/reports\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketresearch.jp\/reports\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketresearch.jp\/reports\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketresearch.jp\/reports\/wp-json\/wp\/v2\/comments?post=55866"}],"version-history":[{"count":2,"href":"https:\/\/www.marketresearch.jp\/reports\/wp-json\/wp\/v2\/posts\/55866\/revisions"}],"predecessor-version":[{"id":58517,"href":"https:\/\/www.marketresearch.jp\/reports\/wp-json\/wp\/v2\/posts\/55866\/revisions\/58517"}],"wp:attachment":[{"href":"https:\/\/www.marketresearch.jp\/reports\/wp-json\/wp\/v2\/media?parent=55866"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketresearch.jp\/reports\/wp-json\/wp\/v2\/categories?post=55866"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketresearch.jp\/reports\/wp-json\/wp\/v2\/tags?post=55866"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}